Showing results (61-70 of 250) with videos related to

Sort By:
Pageof 25
JAMA Network Open|June 7, 2023
Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality DisorderJohannes Lieslehto, Jari Tiihonen, Markku Lähteenvuo, et al.
Journal of Clinical Psychopharmacology|May 31, 2014
Antipsychotic doses among community-dwelling persons with Alzheimer disease in FinlandHeidi Taipale, Marjaana Koponen, Antti Tanskanen, et al.
International Clinical Psychopharmacology|May 27, 2015
Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer's diseaseHeidi Taipale, Marjaana Koponen, Antti Tanskanen, et al.
Schizophrenia Bulletin|July 21, 2021
Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design StudyMarco Solmi, Jari Tiihonen, Markku Lähteenvuo, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 9, 2021
Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer's DiseaseMai Vu, Marjaana Koponen, Heidi Taipale, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 11, 2020
20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)Heidi Taipale, Antti Tanskanen, Juha Mehtälä, et al.
Schizophrenia Bulletin|February 3, 2021
Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective DisorderJonne Lintunen, Heidi Taipale, Antti Tanskanen, et al.
Acta Psychiatrica Scandinavica|April 24, 2023
Association of pharmacological treatments and real-world outcomes in borderline personality disorderJohannes Lieslehto, Jari Tiihonen, Markku Lähteenvuo, et al.
JAMA Psychiatry|November 16, 2022
Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 PatientsMilja Hartikainen, Heidi Taipale, Antti Tanskanen, et al.
Schizophrenia Bulletin|November 5, 2022
Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in FinlandMarco Solmi, Markku Lähteenvuo, Christoph U Correll, et al.
Pageof 25